Rationale: Elexacaftor–tezacaftor–ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane
conductance regulator) modulator combination, developed for patients with CF with at least …

Abstract Information is lacking on the clinical impact of the novel coronavirus, SARS-CoV-2,
on people with cystic fibrosis (CF). Our aim was to characterise SARS-CoV-2 infection in …

With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific
patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 …

Young cystic fibrosis (CF) patients’ airways are mainly colonized by Staphylococcus aureus,
while Pseudomonas aeruginosa predominates in adults. However, the mechanisms behind …

Background The European Medicines Agency has approved the cystic fibrosis transmembrane
conductance regulator (CFTR) modulator combination elexacaftor/tezacaftor/ivacaftor (…

… on medical causes of death produced by CépiDc-Inserm (ICD-10-CM Diagnosis Code: E-84
for CF), we estimated that 285 CF patients died in France between 2007 and 2010 (Martin …

Background Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients
with cystic fibrosis (CF) and advanced pulmonary disease, often leading to suspend the …

Background Around 20% of people with cystic fibrosis (pwCF) do not have access to the triple
combination elexacaftor/tezacaftor/ivacaftor (ETI) in Europe because they do not carry the …

Background The 6 min walk test (6MWT) provides prognostic information in various respiratory
diseases, but limited data exist in cystic fibrosis (CF) adults. Methods Consecutive CF …

Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to the genetic
variants in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. CFTR …